Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

ANVS vs ATHA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ANVS
Annovis Bio, Inc.

Biotechnology

HealthcareNYSE • US
Market Cap$62M
5Y Perf.-52.8%
ATHA
Athira Pharma, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$17M
5Y Perf.-97.4%

ANVS vs ATHA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ANVS logoANVS
ATHA logoATHA
IndustryBiotechnologyBiotechnology
Market Cap$62M$17M
Revenue (TTM)$0.00$0.00
Net Income (TTM)$-29M$-129M
Total Debt$0.00$803K
Cash & Equiv.$19.53B$69M

ANVS vs ATHALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ANVS
ATHA
StockSep 20May 26Return
Annovis Bio, Inc. (ANVS)10047.2-52.8%
Athira Pharma, Inc. (ATHA)1002.6-97.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: ANVS vs ATHA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ANVS and ATHA are tied at the top with 2 categories each — the right choice depends on your priorities. Athira Pharma, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ANVS
Annovis Bio, Inc.
The Growth Play

ANVS has the current edge in this matchup, primarily because of its strength in growth exposure and long-term compounding.

  • EPS growth 99.9%
  • -76.3% 10Y total return vs ATHA's -97.5%
  • 100.4% revenue growth vs ATHA's -64.6%
Best for: growth exposure and long-term compounding
ATHA
Athira Pharma, Inc.
The Income Pick

ATHA is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • beta 1.47
  • Lower volatility, beta 1.47, Low D/E 2.9%, current ratio 1.88x
  • Beta 1.47, current ratio 1.88x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthANVS logoANVS100.4% revenue growth vs ATHA's -64.6%
Stability / SafetyATHA logoATHABeta 1.47 vs ANVS's 2.16
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)ATHA logoATHA+81.6% vs ANVS's +43.7%
Efficiency (ROA)ANVS logoANVS-0.5% ROA vs ATHA's -225.7%

ANVS vs ATHA — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLANVSLAGGINGATHA

Income & Cash Flow (Last 12 Months)

ATHA leads this category, winning 1 of 1 comparable metric.

ANVS and ATHA operate at a comparable scale, with $0 and $0 in trailing revenue.

MetricANVS logoANVSAnnovis Bio, Inc.ATHA logoATHAAthira Pharma, In…
RevenueTrailing 12 months$0$0
EBITDAEarnings before interest/tax-$30M-$110M
Net IncomeAfter-tax profit-$29M-$129M
Free Cash FlowCash after capex-$853M-$52M
Gross MarginGross profit ÷ Revenue
Operating MarginEBIT ÷ Revenue
Net MarginNet income ÷ Revenue
FCF MarginFCF ÷ Revenue
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year+16.7%+24.8%
ATHA leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

ANVS leads this category, winning 2 of 2 comparable metrics.
MetricANVS logoANVSAnnovis Bio, Inc.ATHA logoATHAAthira Pharma, In…
Market CapShares × price$62M$17M
Enterprise ValueMkt cap + debt − cash-$19.5B-$30M
Trailing P/EPrice ÷ TTM EPS-1.62x-0.17x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue
Price / BookPrice ÷ Book value/share0.00x0.37x
Price / FCFMarket cap ÷ FCF
ANVS leads this category, winning 2 of 2 comparable metrics.

Profitability & Efficiency

ANVS leads this category, winning 5 of 5 comparable metrics.

ANVS delivers a -0.7% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-4 for ATHA.

MetricANVS logoANVSAnnovis Bio, Inc.ATHA logoATHAAthira Pharma, In…
ROE (TTM)Return on equity-0.7%-3.8%
ROA (TTM)Return on assets-0.5%-2.3%
ROICReturn on invested capital
ROCEReturn on capital employed-0.3%-2.3%
Piotroski ScoreFundamental quality 0–922
Debt / EquityFinancial leverage0.03x
Net DebtTotal debt minus cash-$19.5B-$68M
Cash & Equiv.Liquid assets$19.5B$69M
Total DebtShort + long-term debt$0$803,000
Interest CoverageEBIT ÷ Interest expense
ANVS leads this category, winning 5 of 5 comparable metrics.

Total Returns (Dividends Reinvested)

ANVS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ANVS five years ago would be worth $967 today (with dividends reinvested), compared to $235 for ATHA. Over the past 12 months, ATHA leads with a +81.6% total return vs ANVS's +43.7%. The 3-year compound annual growth rate (CAGR) favors ANVS at -46.5% vs ATHA's -46.7% — a key indicator of consistent wealth creation.

MetricANVS logoANVSAnnovis Bio, Inc.ATHA logoATHAAthira Pharma, In…
YTD ReturnYear-to-date-37.8%-37.6%
1-Year ReturnPast 12 months+43.7%+81.6%
3-Year ReturnCumulative with dividends-84.7%-84.8%
5-Year ReturnCumulative with dividends-90.3%-97.7%
10-Year ReturnCumulative with dividends-76.3%-97.5%
CAGR (3Y)Annualised 3-year return-46.5%-46.7%
ANVS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

ATHA leads this category, winning 2 of 2 comparable metrics.

ATHA is the less volatile stock with a 1.47 beta — it tends to amplify market swings less than ANVS's 2.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATHA currently trades 51.9% from its 52-week high vs ANVS's 41.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricANVS logoANVSAnnovis Bio, Inc.ATHA logoATHAAthira Pharma, In…
Beta (5Y)Sensitivity to S&P 5002.16x1.47x
52-Week HighHighest price in past year$5.50$8.36
52-Week LowLowest price in past year$1.44$2.30
% of 52W HighCurrent price vs 52-week peak+41.3%+51.9%
RSI (14)Momentum oscillator 0–10063.538.4
Avg Volume (50D)Average daily shares traded889K46K
ATHA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricANVS logoANVSAnnovis Bio, Inc.ATHA logoATHAAthira Pharma, In…
Analyst RatingConsensus buy/hold/sell
Price TargetConsensus 12-month target
# AnalystsCovering analysts
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ANVS leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). ATHA leads in 2 (Income & Cash Flow, Risk & Volatility).

Best OverallAnnovis Bio, Inc. (ANVS)Leads 3 of 6 categories
Loading custom metrics...

ANVS vs ATHA: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Which is the better long-term investment — ANVS or ATHA?

Over the past 5 years, Annovis Bio, Inc.

(ANVS) delivered a total return of -90. 3%, compared to -97. 7% for Athira Pharma, Inc. (ATHA). Over 10 years, the gap is even starker: ANVS returned -76. 3% versus ATHA's -97. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

02

Which is safer — ANVS or ATHA?

By beta (market sensitivity over 5 years), Athira Pharma, Inc.

(ATHA) is the lower-risk stock at 1. 47β versus Annovis Bio, Inc. 's 2. 16β — meaning ANVS is approximately 47% more volatile than ATHA relative to the S&P 500.

03

Which is growing faster — ANVS or ATHA?

On earnings-per-share growth, the picture is similar: Annovis Bio, Inc.

grew EPS 99. 9% year-over-year, compared to 2. 0% for Athira Pharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

04

Which has better profit margins — ANVS or ATHA?

Annovis Bio, Inc.

(ANVS) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Athira Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANVS leads at 0. 0% versus 0. 0% for ATHA. At the gross margin level — before operating expenses — ANVS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — ANVS or ATHA?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

06

Is ANVS or ATHA better for a retirement portfolio?

For long-horizon retirement investors, Athira Pharma, Inc.

(ATHA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Annovis Bio, Inc. (ANVS) carries a higher beta of 2. 16 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATHA: -97. 5%, ANVS: -76. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between ANVS and ATHA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

ANVS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ATHA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.